NCT03008408View on ClinicalTrials.gov

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 18, 2017

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Recurrent Endometrial CarcinomaRecurrent Endometrial Endometrioid AdenocarcinomaRefractory Endometrial CarcinomaRefractory Endometrial Endometrioid AdenocarcinomaStage III Uterine Corpus Cancer AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8Stage IIIB Uterine Corpus Cancer AJCC v8Stage IIIC Uterine Corpus Cancer AJCC v8Stage IIIC1 Uterine Corpus Cancer AJCC v8Stage IIIC2 Uterine Corpus Cancer AJCC v8Stage IV Uterine Corpus Cancer AJCC v8Stage IVA Uterine Corpus Cancer AJCC v8Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
DRUG

Everolimus

Given PO

DRUG

Letrozole

Given PO

DRUG

Ribociclib

Given PO

Trial Locations (2)

77030

M D Anderson Cancer Center, Houston

77026-1967

Lyndon Baines Johnson General Hospital, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER